These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 11109184)

  • 1. Pharmaceutical expenditure in Spain: cost and control.
    Lopez Bastida J; Mossialos E
    Int J Health Serv; 2000; 30(3):597-616. PubMed ID: 11109184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical expenditure and therapeutic value of new medicines in Spain.
    Darba J
    Pharmacoeconomics; 2003; 21(16):1211-2. PubMed ID: 14594440
    [No Abstract]   [Full Text] [Related]  

  • 4. Incentives and pharmaceutical reimbursement reforms in Spain.
    Puig-Junoy J
    Health Policy; 2004 Feb; 67(2):149-65. PubMed ID: 14720633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Drug expenditures of pensioners in 1997-2000].
    Swistak P; Błońska-Fajfrowska B
    Wiad Lek; 2003; 56(1-2):85-8. PubMed ID: 12901276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug cost containment policies in Italy: are they really effective in the long-run? The case of minimum reference price.
    Atella V
    Health Policy; 2000 Jan; 50(3):197-218. PubMed ID: 10827308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The drug budget silo mentality: the French case.
    Le Pen C
    Value Health; 2003; 6 Suppl 1():S10-9. PubMed ID: 12846922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost containment interventions introduced on the community drugs schemes in Ireland-evaluation of expenditure trends using a national prescription claims database.
    Usher C; Tilson L; Bennett K; Barry M
    Clin Ther; 2012 Mar; 34(3):632-9. PubMed ID: 22381716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prescription drugs: issues of cost, coverage, and quality.
    Copeland C
    EBRI Issue Brief; 1999 Apr; (208):1-21. PubMed ID: 10539445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specialty pharmacy management adjusts to new financial realities.
    Reinke T
    Manag Care; 2013 Apr; 22(4):13-4. PubMed ID: 23678558
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmaceutical management strategies of industrialized countries.
    Brier KL
    Formulary; 1995 Oct; 30(10):606-10, 614. PubMed ID: 10151724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The way to economic prescribing.
    Ryan M; Yule B
    Health Policy; 1993 Sep; 25(1-2):25-38. PubMed ID: 10129157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmaceutical expenditure in Spain: evolution and cost containment measures during 1998-2001.
    Darbà J
    Eur J Health Econ; 2003 Sep; 4(3):151-7. PubMed ID: 15609181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The UK pharmaceutical market. An overview.
    Towse A
    Pharmacoeconomics; 1996; 10 Suppl 2():14-25. PubMed ID: 10163432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical cost-containment policy: experiences in Shanghai, China.
    Hu S; Chen W; Cheng X; Chen K; Zhou H; Wang L
    Health Policy Plan; 2001 Dec; 16 Suppl 2():4-9. PubMed ID: 11772985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
    Davidova J; Praznovcova L; Lundborg CS
    Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs.
    Grootendorst PV; Marshall JK; Holbrook AM; Dolovich LR; O'Brien BJ; Levy AR
    Health Serv Res; 2005 Oct; 40(5 Pt 1):1297-317. PubMed ID: 16174135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lessons from international experience in controlling pharmaceutical expenditure. I: Influencing patients.
    Freemantle N; Bloor K
    BMJ; 1996 Jun; 312(7044):1469-71. PubMed ID: 8664631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in prescription drug expenditures by Medicaid enrollees.
    Banthin JS; Miller GE
    Med Care; 2006 May; 44(5 Suppl):I27-35. PubMed ID: 16625061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spending on medicines in Israel in an international context.
    Sax P
    Isr Med Assoc J; 2005 May; 7(5):286-91. PubMed ID: 15909459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.